#AS­CO19: Hey Pfiz­er, No­var­tis is go­ing af­ter your block­buster can­cer fran­chise — and they have pos­i­tive OS da­ta

CHICA­GO — No­var­tis came to AS­CO play­ing catchup on the breast can­cer front. And they’re leav­ing with a ma­jor ad­vance for the cam­paign.

In an up­date on their drug Kisqali com­bined with en­docrine ther­a­py, re­searchers high­light­ed a 70.2% sur­vival rate among pre-menopausal women with hor­mone re­cep­tor pos­i­tive, hu­man epi­der­mal growth fac­tor re­cep­tor-2 neg­a­tive (HR+/HER2-) ad­vanced or metasta­t­ic breast can­cer 42 months af­ter treat­ment be­gan. That’s sig­nif­i­cant­ly bet­ter — with a 27% drop in the risk of death — than the for­mer stan­dard of care, where 46% of pa­tients in the Monaleesa-7 con­trol arm were still alive.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.